Adiponectin gene polymorphisms and susceptibility to diabetic nephropathy: A meta-analysis

Renal Failure

Volumn 36, Issue 3, 2014, Pages 478-487

  Lin, Zi ^a   Huang, Guoliang ^a   Zhang, Jingwen ^a   Lin, Xiaoyu ^a  

^a FUJIAN MEDICAL UNIVERSITY   (China)

Author keywords

Adiponectin; Diabetes; Gene polymorphisms; Meta analysis; Nephropathy

Indexed keywords

ADIPONECTIN; ALANINE; CYSTEINE; GUANINE; THREONINE;

ALLELE; BIBLIOGRAPHIC DATABASE; CAUCASIAN; CNKI DATABASE; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; EMBASE; ETHNICITY; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HUMAN; MEDLINE; META ANALYSIS; PRIORITY JOURNAL; PUBLISHING; REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; ASIAN CONTINENTAL ANCESTRY GROUP; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETICS; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

ADIPONECTIN; ASIAN CONTINENTAL ANCESTRY GROUP; DIABETIC NEPHROPATHIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; PUBLICATION BIAS; RISK FACTORS;

EID: 84896463924     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/0886022X.2013.868319     Document Type: Review

References (55)

1. Remuzzi G, Schieppati A, Ruggenenti P. Clinical practice. Nephropathy in patients with type 2 diabetes. N Engl J Med. 2002;346(15):1145-1151.
2. Tahrani AA, Bailey CJ, Del Prato S, Barnett AH. Management of type 2 diabetes: new and future developments in treatment. Lancet. 2011;378(9786):182- 197.
3. Nyenwe EA, Jerkins TW, Umpierrez GE, Kitabchi AE. Management of type 2 diabetes: evolving strategies for the treatment of patients with type 2 diabetes. Metabolism. 2011;60(1):1-23.
4. Maeda S, Imamura M, Kurashige M, et al. Replication study for the association of 3 SNP loci identified in a genome-wide association study for diabetic nephropathy in European type 1 diabetes with diabetic nephropathy in Japanese patients with type 2 diabetes. Clin Exp Nephrol. 2013. [Epub ahead of print]. doi: 10.1007/ s10157-013-0797-5.
5. Yang S, Zhang J, Feng C, Huang G. MTHFR 677T variant contributes to diabetic nephropathy risk in Caucasian individuals with type 2 diabetes: a meta-analysis. Metabolism. 2013; 62(4):586-594.
6. Sandholm N, Salem RM, McKnight AJ, et al. New susceptibility loci associated with kidney disease in type 1 diabetes. PLoS Genet. 2012;8(9):e1002921.
7. Karadeniz M, Erdogan M, Cetinkalp S, Berdeli A, Eroglu Z, Ozgen AG. Monocyte chemoattractant protein-1 (MCP-1) 2518G/A gene polymorphism in Turkish type 2 diabetes patients with nephropathy. Endocrine. 2010;37(3):513-517.
8. Vionnet N, Tregouët D, Kazeem G, et al. Analysis of 14 candidate genes for diabetic nephropathy on chromosome 3q in European populations: strongest evidence for association with a variant in the promoter region of the adiponectin gene. Diabetes. 2006; 55(11):3166-3174.
9. Zhang D, Ma J, Brismar K, Efendic S, Gu HF. A single nucleotide polymorphism alters the sequence of SP1 binding site in the adiponectin promoter region and is associated with diabetic nephropathy among type 1 diabetic patients in the Genetics of Kidneys in Diabetes Study. J Diabetes Complications. 2009; 23(4):265-272.
10. Zhang D, Efendic S, Brismar K, Gu HF. Effects of MCF2L2, ADIPOQ and SOX2 genetic polymorphisms on the development of nephropathy in type 1 Diabetes Mellitus. BMC Med Genet. 2010; 11:116.
11. Chu H, Wang M, Zhong D, et al. AdipoQ polymorphisms are associated with type 2 diabetes mellitus: a meta-analysis study. Diabetes Metab Res Rev. 2013;29(7):532-545.
12. Qi L, Li T, Rimm E, et al. The +276 polymorphism of the APM1 gene, plasma adiponectin concentration, and cardiovascular risk in diabetic men. Diabetes. 2005;54(5):1607-1610.
13. Francke S, Manraj M, Lacquemant C, et al. A genome-wide scan for coronary heart disease suggests in Indo-Mauritians a susceptibility locus on chromosome 16p13 and replicates linkage with the metabolic syndrome on 3q27. Hum Mol Genet. 2001; 10(24):2751-2765.
14. Fumeron F, Aubert R, Siddiq A, et al. Epidemiologic Data on the Insulin Resistance Syndrome (DESIR) Study Group: adiponectin gene polymorphisms and adiponectin levels are independently associated with the development of hyperglycemia during a 3-year period: the epidemiologic data on the insulin resistance syndrome prospective study. Diabetes. 2004; 53(4):1150-1157.
15. Menzaghi C, Trischitta V, Doria A. Genetic influences of adiponectin on insulin resistance, type 2 diabetes, and cardiovascular disease. Diabetes. 2007;56(5):1198-1209.
16. Jaziri R, Aubert R, Roussel R, et al. Association of ADIPOQ genetic variants and plasma adiponectin isoforms with the risk of incident renal events in type 2 diabetes. Nephrol Dial Transplant. 2010;25(7):2231-2237.
17. Choe EY,Wang HJ, Kwon O, et al. Variants of the adiponectin gene and diabetic microvascular complications in patients with type 2 diabetes. Metabolism. 2013;62(5):677-685.
18. Wu LS, Hsieh CH, Pei D, Hung YJ, Kuo SW, Lin E. Association and interaction analyses of genetic variants in ADIPOQ, ENPP1, GHSR, PPARgamma and TCF7L2 genes for diabetic nephropathy in a Taiwanese population with type 2 diabetes. Nephrol Dial Transplant. 2009;24(11):3360-3366.
19. Ma J, Möllsten A, Falhammar H, et al. Genetic association analysis of the adiponectin polymorphisms in type 1 diabetes with and without diabetic nephropathy. J Diabetes Complications. 2007; 21(1):28-33.
20. Yoshioka K, Yoshida T, Umekawa T, et al. Adiponectin gene polymorphism (G276T) is not associated with incipient diabetic nephropathy in Japanese type 2 diabetic patients. Metabolism. 2004;53(9):1223-1226.
21. Blech I, Katzenellenbogen M, Katzenellenbogen A, et al. Predicting diabetic nephropathy using a multifactorial genetic model. PLoS One. 2011;6(4):e18743.
22. Ranjbar SH, Amoli MM, Sajadi M, et al. Genetic association analysis of the adiponectin polymorphisms in type 2 diabetes with and without complications. Iran J Diabetes Lipid Disord. 2011;10: 1-4.
23. Guo Z, Wu S, Sun Y. Relationship between single nucleotide polymorphism at position 276 in adiponectin gene and type 2 diabetic nephropathy. J Shanxi Med Univ. 2008;39(6):507-510. [in Chinese].
24. Min Y, Chen J, Zhu L, Li X, Wei J, Su K. Association of SNP- 11377C/G in proximal promoter region of adiponectin gene with type 2 diabetic nephropathy. Shandong Med J. 2011;5:65-66. [in Chinese].
25. Lin J, Shi Y, Li Y, Tao G. Association of gene polymorphism in promoter region of adiponectin gene and albuminuria in patients with type 2 diabetes mellitus. Chin J Diabetes Mellitus. 2010; 2(2):106-110. [in Chinese].
26. Peng C, Hong Y, Fu L. Association of adiponectin gene polymorphism in type 2 diabetes with nephropathy. J Med Res. 2012;41(4):156-159. [in Chinese].
27. Bostrom MA, Freedman BI, Langefeld CD, Liu L, Hicks PJ, Bowden DW. Association of adiponectin gene polymorphisms with type 2 diabetes in an African American population enriched for nephropathy. Diabetes. 2009;58(2):499-504.
28. Prior SL, Javid J, Gill GV, Bain SC, Stephens JW. The adiponectin rs17300539 G4A variant and nephropathy risk. Kidney Int. 2008; 74(10):1361.
29. Zhao H, Chen L, Zhang C, Han J. Polymorphism in the 50promoter region of the APN gene contributes to development of type 2 diabetes nephropathy. Proc Clin Med. 2008;1(7):483-485. [in Chinese].
30. Jia M, Feng X, Zhang Z, Qiao B, Qin X, Sun Y. Correlation of polymorphism of adiponectin promoter with diabetes type 2 and its complications. Chin J Lab Med. 2008;31(2):163-169. [in Chinese].
31. Jorsal A, Tarnow L, Frystyk J, et al. Serum adiponectin predicts all-cause mortality and end stage renal disease in patients with type I diabetes and diabetic nephropathy. Kidney Int. 2008; 74(5):649-654.
32. Rudofsky Jr G, Schlimme M, Schlotterer A, et al. No association of the 94T/G polymorphism in the adiponectin gene with diabetic complications. Diabetes Obes Metab. 2005;7(4):455-459.
33. Gu HF, Alvarsson A, Efendic S, Brismar K. SOX2 has genderspecific genetic effects on diabetic nephropathy in samples from patients with type 1 diabetes mellitus in the GoKinD study. Gend Med. 2009;6(4):555-564.
34. Gu HF. Biomarkers of adiponectin: plasma protein variation and genomic DNA polymorphisms. Biomark Insights. 2009;4:123-133.
35. Higgins JPT, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557-560.
36. Cochran WG. The combination of estimates from different experiments. Biometrics. 1954;10:101-129.
37. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-188.
38. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959; 22(4):719-748.
39. Tobias A. Assessing the influence of a single study in the metaanalysis estimate. Stata Tech Bull. 1999;8:15-17.
40. Stuck AE, Rubenstein LZ, Wieland D. Bias in meta-analysis detected by a simple, graphical test. Asymmetry detected in funnel plot was probably due to true heterogeneity. BMJ. 1998; 316(7129):469-471.
41. Bowden J, Tierney JF, Copas AJ, Burdett S. Quantifying, displaying and accounting for heterogeneity in the meta-analysis of RCTs using standard and generalised Q statistics. BMC Med Res Methodol. 2011;11:41.
42. Chung HF, Chen PS, Long K, Hsu CC, Huang MC. The association of ADIPOQ gene polymorphisms and clinical risk factors with nephropathy progression in type 2 diabetes. Meeting Abstracts. Experimental Biology 2012, EB, San Diego, CA, Apr 21-25, 2012.
43. Hasslacher C, Ritz E, Wahl P, Michael C. Similar risks of nephropathy in patients with type I or type II diabetes mellitus. Nephrol Dial Transplant. 1989;4:859-863.
44. Makita Y, Moczulski DK, Bochenski J, Smiles AM, Warram JH, Krolewski AS. Methylenetetrahydrofolate reductase gene polymorphism and susceptibility to diabetic nephropathy in type 1 diabetes. Am J Kidney Dis. 2003;41(6):1189-1194.
45. Wang L, Teng Z, Cai S, Wang D, Zhao X, Yu K. The association between the PPARg2 Pro12Ala polymorphism and nephropathy susceptibility in type 2 diabetes: a meta-analysis based on 9,176 subjects. Diagn Pathol. 2013;8(1):118 (1-7). doi: 10.1186/1746- 1596-8-118.
46. Freedman BI, Tuttle AB, Spray BJ. Familial predisposition to nephropathy in African-Americans with non-insulin-dependent diabetes mellitus. Am J Kidney Dis. 1995;25(5):710-713.
47. Österholm AM, He B, Pitkaniemi J, et al. Genome-wide scan for type 1 diabetic nephropathy in the Finnish population reveals suggestive linkage to a single locus on chromosome 3q. Kidney Int. 2007;71(2):140-145.
48. Freedman BI, Bostrom M, Daeihagh P, Bowden DW. Genetic factors in diabetic nephropathy. Clin J Am Soc Nephrol. 2007; 2(6):1306-1316.
49. McKillop AM, Flatt PR. Recent developments in the search for biomarkers for the diagnosis and monitoring of diabetes. Recent Pat Endocr Metab Immune Drug Discov. 2008; 2(3):172-177.
50. Yamagishi SI, Fukami K, Ueda S, Okuda S. Molecular mechanisms of diabetic nephropathy and its therapeutic intervention. Curr Drug Targets. 2007;8(8):952-959.
51. Jee SH, Sull JW, Lee JE, et al. Adiponectin concentrations: a genome-wide association study. Am J Hum Genet. 2010; 87(4):545-552.
52. Ling H, Waterworth DM, Stirnadel HA, et al. Genome-wide linkage and association analyses to identify genes influencing adiponectin levels: the GEMS Study. Obesity. 2009;17(4):737-744.
53. Richards JB, Waterworth D, O'Rahilly S, et al. A genome-wide association study reveals variants in ARL15 that influence adiponectin levels. PLoS Genet. 2009;5(12):e1000768.
54. Heid IM, Wagner SA, Gohlke H, et al. Genetic architecture of the APM1 gene and its influence on adiponectin plasma levels and parameters of the metabolic syndrome in 1,727 healthy Caucasians. Diabetes. 2006;55(2):375-384.
55. Laumen H, Saningong AD, Heid IM, et al. Functional characterization of promoter variants of the adiponectin gene complemented by epidemiological data. Diabetes. 2009;58(4):984-991.